Why the study?
Do specific gene mutations (LPL, PPARalpha, apo E, PPARgamma) affect the lipid-lowering response to fenofibrate in hypertriglyceridemic patients?
Do specific gene mutations (LPL, PPARalpha, apo E, PPARgamma) affect the lipid-lowering response to fenofibrate in hypertriglyceridemic patients?
Genetic variations in genes encoding proteins involved in triglyceride-rich lipoprotein metabolism, such as LPL and apo E, can significantly modulate the lipid-lowering response to fenofibrate.
Answers are grounded in this paper and cite their sources.
LPL-P207L carriers may show suboptimal fenofibrate response; hypothesis-generating for pharmacogenetic testing in hypertriglyceridemia.
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist which regulates the transcription of genes encoding proteins involved in triglyceride (TG)-rich lipoproteins and lipoprotein lipase (LPL) metabolism. The aim of the present study was to investigate the relation between TG-related parameters considered in different clinical guidelines used in industrialized countries for the management of lipid disorders (namely fasting plasma TG, high density-lipoprotein cholesterol (HDL-C), non-HDL-C concentrations and total-C/HDL-C ratio) and the presence of LPL-null (P207L), LPL-defective (D9N), PPARalpha -L162V, apolipoprotein (apo) E and PPARgamma-P12A gene mutations, in a sample of 292 hypertriglyceridemic subjects treated with fenofibrate for 3 months. Although fenofibrate induced a decrease in plasma TG level and an increase in HDL-C level in all studied genotypes, mutation-specific differences were observed. After adjustment for age, gender, body mass index and the presence of apo E2 genotype, the LPL-P207L mutation was associated with residual post-treatment hypertriglyceridemia [TG > 2.0 mmol/l, odds ratio (OR) = 3.07, P = 0.005] and total-C/HDL-C ratio > 5 (OR = 2.68; P = 0.03). This effect was significantly related to higher plasma TG concentrations at baseline among carriers of a LPL-null mutation. Compared to apo E3 and E4 variants, the apo E2 allele was associated with a better response to fenofibrate on all lipid parameter, especially among PPARalpha -L162V carriers, whereas the simultaneous presence of apo E2 and PPARalpha -L162V tended to improve fenofibrate response among LPL-P207L heterozygotes. Finally, the LPL-D9N and PPARgamma -P12A mutations did not affect fenofibrate lipid-lowering action. This study suggests that frequent genetic variations in genes encoding proteins involved in TG-rich lipoprotein metabolism could modulate the response to fenofibrate treatment, as defined in clinical guidelines.
No takes yet. Share an insight, caveat, or question.
Brisson et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: